Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Hum Hypertens ; 22(11): 781-7, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18633427

ABSTRACT

Aortic valve sclerosis (AVS) may predispose to a prothrombotic state, as AVS is predictor of cardiovascular events in hypertensive populations. Thrombin exerts non-thrombotic effects such as vessel tone regulation, progression of atherosclerosis and stimulation of atrial natriuretic peptide (ANP) secretion. We hypothesized that hypertensive patients with AVS may have a persistently activated thrombin generation. We studied 234 asymptomatic never-treated hypertensive patients (73 of them with AVS). Prothrombin F1+2 (F1+2), as a marker of thrombin generation and fibrin D-dimer, as a marker of thrombus formation, ANP and brain natriuretic peptide (BNP) were measured. Presence of AVS, aortic jet velocity and left ventricular diameter at diastole were determined by echocardiography. Glomerular filtration rate was estimated using the Modification of Diet in Renal Disease formula. F1+2 (median and interquartile range (IQR) = 1.05, 0.87-1.38 nM vs. 0.93, 0.72-1.16) and ANP (22, 14-37 pg ml(-1) vs. 17, 11-25) levels were greater, and glomerular filtration rate values (65+/-9 ml min(-1)/1.73 m2 vs. 68+/-11) were lower in hypertensive patients with AVS than in those without AVS. F1+2 (odds ratio, 95% CI = 2.94, 1.07-8.6) was independently associated with AVS after being adjusted for age, gender and the variables of cardiorenal functions measured. After 6 months of treatment using valsartan, F1+2 levels remained elevated in hypertensive patients with AVS (1.14, 0.83-1.42 nM vs. 1.07, 0.84-1.5, n=19), but decreased in those without AVS (1.01, 0.85-1.31 vs. 0.8, 0.84-1.78, n=27). Thrombin generation was associated with AVS in untreated hypertensive patients, and this association was persistent after blood-pressure-lowering treatment using valsartan.


Subject(s)
Aortic Valve/pathology , Heart Valve Diseases/etiology , Hypertension/blood , Thrombin/metabolism , Aortic Valve/diagnostic imaging , Biomarkers/blood , Blood Pressure/physiology , Echocardiography , Female , Follow-Up Studies , Heart Valve Diseases/blood , Heart Valve Diseases/diagnosis , Heart Ventricles/diagnostic imaging , Heart Ventricles/physiopathology , Humans , Hypertension/complications , Hypertension/physiopathology , Immunoenzyme Techniques , Male , Middle Aged , Prognosis , Retrospective Studies , Sclerosis
2.
J Hum Hypertens ; 22(4): 275-81, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18075518

ABSTRACT

Plasma levels of von Willebrand factor (vWF), a marker of endothelial dysfunction/damage, are elevated in high-risk hypertensive patients and in patients with severe aortic regurgitation (AR). Patients with mild-to-moderate AR, frequently detected in hypertensive elderly, have additional left ventricular morphological and functional dysfunctions. We hypothesized that hypertensive patients with mild-to-moderate AR may have enhanced endothelial and/or left ventricular dysfunctions that may lead to a deteriorated prognosis. We measured vWF, prothrombin F1+2 (F 1+2) as a marker of thrombin generation, brain natriuretic peptide (BNP) in 104 hypertensive patients with mild-to-moderate AR and 66 hypertensive patients without AR. The left ventricular diameter at systole (LVDs) and left ventricular posterior wall thickness (LVWT) were determined by echocardiography and indexed by body surface area (LVDs/BSA and LVWT/BSA). VWF (median, interquartile range (IQR) 154, 120-196%) and BNP (34.7 pg ml(-1), 15-65%) levels were greater in patients with AR than in those without AR (135, 98-175% and 20, 10.3-49 pg ml(-1)). All patients were prospectively followed up for cardiac events during the period of median 43 months (IQR 31-81). Patients with AR had an increased risk of cardiac events (regression ratio (RR) 1.87, 95% confidence interval 1.28-2.87) when compared to those without AR. A multivariate Cox hazard analysis indicated that log vWF (RR 4.93) and log BNP (RR 1.9) were independent predictors in patients with AR. VWF was an independent predictor of clinical outcome in hypertensive patients with mild-to-moderate AR.


Subject(s)
Aortic Valve Insufficiency/complications , Blood Pressure/physiology , Hypertension/blood , von Willebrand Factor/metabolism , Aged , Aortic Valve Insufficiency/diagnostic imaging , Aortic Valve Insufficiency/physiopathology , Biomarkers/blood , Echocardiography , Endothelium, Vascular/physiopathology , Female , Follow-Up Studies , Humans , Hypertension/complications , Hypertension/physiopathology , Male , Prognosis , Prospective Studies , Severity of Illness Index , Ventricular Dysfunction, Left/diagnostic imaging , Ventricular Dysfunction, Left/etiology , Ventricular Dysfunction, Left/physiopathology
3.
Intern Med ; 35(7): 564-8, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8842764

ABSTRACT

We encountered a case of familial juvenile gouty nephropathy (FJGN) with an autosomal dominant transmission pattern. Hyperuricemia in the propositus was caused by renal underexcretion of urate although his erythrocyte purine enzyme was normal. A renal biopsy specimen from the propositus showed interstitial fibrosis with tubular atrophy. On pyrazinamide and probenecid tests, the tubular secretion of urate selectively decreased without changes in either presecretory or postsecretory reabsorption of urate when his renal function was normal. Probenecid increased the urinary urate excretion and Cur/Ccr. The serum urate concentration was poorly controlled by allopurinol. When his renal function deteriorated, the uricosuric effects of both probenecid and benzbromarone were attenuated. However, the combined administration of probenecid with allopurinol decreased the serum urate concentration. These data suggest that the tubular secretion of urate is selectively impaired in FJGN and at the stage of renal failure, the combination of an uricosuric agent with allopurinol might be effective in treating hyperuricemia in FJGN.


Subject(s)
Gout/genetics , Gout/metabolism , Kidney Failure, Chronic/genetics , Kidney Failure, Chronic/metabolism , Kidney/metabolism , Uric Acid/metabolism , Adolescent , Benzbromarone/therapeutic use , Female , Genes, Dominant , Gout/drug therapy , Gout Suppressants/therapeutic use , Humans , Kidney/pathology , Kidney Failure, Chronic/drug therapy , Male , Pedigree , Probenecid/therapeutic use , Pyrazinamide/therapeutic use , Renal Agents/therapeutic use , Uricosuric Agents/therapeutic use
4.
Eur J Pharmacol ; 191(3): 369-73, 1990 Dec 04.
Article in English | MEDLINE | ID: mdl-1982270

ABSTRACT

The use-dependent effects of bunazosin on the maximal rate of rise (Vmax) of the action potential and conduction velocity were studied in isolated papillary muscles of guinea-pig. Standard microelectrode techniques were used to monitor the conduction and action potential of the muscles. In the presence of 30 microM bunazosin, the time constants for the start of the use-dependent inhibition of Vmax during a 0.2, 1, 2 and 3 Hz stimulation were (means +/- S.E.M. in s) 30.9 +/- 8.0, 15.0 +/- 1.6, 7.4 +/- 0.9 and 3.9 +/- 0.7 (n = 4) and those for conduction velocity were 17.3 +/- 2.3, 17.3 +/- 5.2, 6.5 +/- 0.9 and 3.4 +/- 0.2, respectively. These results showed that in the cardiac ventricular muscle of the guinea-pigs, bunazosin produces use-dependent changes in conduction velocity with onset kinetics comparable to those measured simultaneously using Vmax. The characteristics of the use-dependent inhibition of conduction velocity induced by bunazosin are similar to those found with slow kinetic drugs such as disopyramide rather than with fast ones.


Subject(s)
Adrenergic alpha-Antagonists/pharmacology , Heart Conduction System/drug effects , Quinazolines/pharmacology , Action Potentials/drug effects , Animals , Guinea Pigs , In Vitro Techniques , Kinetics , Membrane Potentials/drug effects , Papillary Muscles/drug effects
5.
Eur J Pharmacol ; 179(3): 447-51, 1990 Apr 25.
Article in English | MEDLINE | ID: mdl-2163858

ABSTRACT

Under whole cell patch conditions, 1389-S blocked the INa in guinea-pig ventricular myocytes under steady state conditions (Kdrest = 30 microM, Kdi = 2.4 microM) with a shift of the inactivation curve to the hyperpolarizing direction. Both brief and long conditioning pulses could produce a use-dependent block of 1389-S. These results suggest that 1389-S had a higher affinity to the inactivated than to the rested state under steady state conditions and had a higher affinity to the activated state during train pulses as well as to the inactivated state, making channels unavailable for conduction upon activation.


Subject(s)
Myocardium/metabolism , Propanolamines/pharmacology , Sodium Channels/drug effects , Animals , Electric Stimulation , Guinea Pigs , Heart/drug effects , Heart/physiology , In Vitro Techniques , Myocardium/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...